Filing Details

Accession Number:
0000899243-20-003296
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-05 17:00:23
Reporting Period:
2020-02-03
Accepted Time:
2020-02-05 17:00:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1351288 Gw Pharmaceuticals Plc GWPH Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1754129 D. Justin Gover Sovereign House, Vision Park, Histon
Cambridge X0 CB24 9BZ
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2020-02-03 202,224 $0.00 765,749 No 4 M Direct
Ordinary Shares Disposition 2020-02-03 71,712 $9.57 694,037 No 4 S Direct
Ordinary Shares Disposition 2020-02-03 110,964 $9.63 583,073 No 4 S Direct
Ordinary Shares Disposition 2020-02-03 19,548 $9.71 563,525 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Options Disposition 2020-02-03 202,224 $0.00 202,224 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7 2019-02-15 2020-03-15 No 4 M Direct
Footnotes
  1. Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer.
  2. Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of February 3, 2020.
  3. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2019.
  4. Represented by ADSs.
  5. The price reported in Column 4 is a weighted average price per ordinary share ($114.85 per ADS). These share were sold in multiple transactions at prices ranging from $9.51 per ordinary share ($114.16 per ADS) to $9.60 per ordinary share ($115.15 per ADS), inclusive. The Reporting Person understands to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  6. The price reported in Column 4 is a weighted average price per ordinary share ($115.52 per ADS). These share were sold in multiple transactions at prices ranging from $9.60 per ordinary share ($115.16 per ADS) to $9.68 per ordinary share ($116.14 per ADS), inclusive. The Reporting Person understands to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  7. The price reported in Column 4 is a weighted average price per ordinary share ($116.54 per ADS). These share were sold in multiple transactions at prices ranging from $9.68 per ordinary share ($116.19 per ADS) to $9.76 per ordinary share ($117.07 per ADS), inclusive. The Reporting Person understands to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.